171 terminated. 171 Phase 1, 65 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 171 | Terminated 171 |
| Phase 2 | 65 | Terminated 65 |
Follow Urologic Neoplasms: new trials by email Literature Review of Urologic Neoplasms trials Research Report on Urologic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intervention of Bladder Cancer by CAR-T 4SCAR-PSMA, 4SCAR-FRa - Bladder Cancer, Urothelial Carcinoma Bladder | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 20 | 2025-08-01 | 2026-10-30 |
| A Phase 1 Trial of ADI-270 in ccRCC ADI-270, Fludarabine, Cyclophosphamide - Clear Cell Renal Cell Carcinoma | Phase 1 | Terminated | Adicet Therapeutics | 10 | 2024-12-12 | 2026-10-27 |
| A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer PF-07921585, Sasanlimab - Non Small Cell Lung Cancer, Bladder Cancer | Phase 1 | Terminated | Pfizer | 4 | 2024-11-11 | 2026-03-23 |
| A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell Carcinoma Temferon, Pembrolizumab, Cabozantinib - Clear Cell RCC | Phase 1 / Phase 2 | Terminated | Genenta Science | 10 | 2024-10-22 | 2026-02-09 |
| A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors XL495, ADC cytotoxic agents - Solid Cancers, Solid Tumor Cancer | Phase 1 | Terminated | Exelixis | 9 | 2024-10-17 | 2025-06-25 |
| A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines. PF-07826390, sasanlimab, SOC (anti-PD-1 + platinum -based chemo) - Neoplasms, Non-small-cell Lung Cancer | Phase 1 | Terminated | Pfizer | 10 | 2024-09-06 | 2026-02-23 |
| A Study of APL-1501 Extended Release Capsules Compared to APL-1202 Immediate Release Tablets in Healthy Volunteers APL-1202, APL-1501 - Healthy Volunteers | Phase 1 | Terminated | Syneos Health | 12 | 2024-06-21 | 2025-01-31 |
| A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors ACTM-838 - Solid Tumor | Phase 1 | Terminated | Actym Therapeutics, Inc. | 10 | 2024-06-05 | 2025-10-15 |
| A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination PF-07329640, sasanlimab, bevacizumab - Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer | Phase 1 | Terminated | Pfizer | 4 | 2024-05-09 | 2024-11-06 |
| NM32-2668 in Adult Patients With Selected Advanced Solid Tumors NM32-2668 - Ovarian Carcinoma, Fallopian Tube Carcinoma | Phase 1 | Terminated | Numab Therapeutics AG | 11 | 2024-05-01 | 2025-07-23 |
| A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors PF-07820435, Sasanlimab - Neoplasms, Non-small-cell Lung Cancer | Phase 1 | Terminated | Pfizer | 9 | 2024-02-08 | 2025-09-17 |
| A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors ABBV-303, Budigalimab - Solid Tumors | Phase 1 | Terminated | AbbVie | 27 | 2024-02-06 | 2025-10-27 |
| Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types MT-8421, Nivolumab - Non Small Cell Lung Cancer, Hepatocellular Carcinoma | Phase 1 | Terminated | Molecular Templates, Inc. | 15 | 2023-11-01 | 2024-11-01 |
| Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies BDC-3042, Cemiplimab - Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma | Phase 1 | Terminated | Bolt Biotherapeutics, Inc. | 17 | 2023-10-11 | 2025-11-17 |
| Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant Degarelix, Gemcitabine/Cisplatin - Urothelial Carcinoma Bladder, Androgen Receptor Positive | Phase 1 | Terminated | Brown University | 2 | 2023-10-02 | 2026-04-02 |
| Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors INCB 99280 with Ipilimumab - Melanoma, Hepatocellular Carcinoma (HCC) | Phase 1 | Terminated | Incyte Corporation | 8 | 2023-08-29 | 2025-02-18 |
| A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies AUR106 - Relapse, Advanced Malignant Neoplasm | Phase 1 | Terminated | Aurigene Discovery Technologies Limited | 21 | 2023-08-26 | 2026-04-17 |
| Study of RO7515629 in Participants With HLA-G Positive Solid Tumors RO7515629, tocilizumab - Renal Cell Carcinoma, Non-small Cell Lung Cancer | Phase 1 | Terminated | Hoffmann-La Roche | 3 | 2023-06-15 | 2024-07-09 |
| A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors QEQ278 - Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell | Phase 1 | Terminated | Novartis Pharmaceuticals | 30 | 2023-04-04 | 2026-02-17 |
| A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically OMX-0407 - Solid Tumor | Phase 1 / Phase 2 | Terminated | iOmx Therapeutics AG | 68 | 2023-03-30 | 2026-07-24 |
Showing 20 of 171. Sign in to see all of them.
Carcinoma, Renal Cell (113) · Carcinoma, Non-Small-Cell Lung (55) · Urinary Bladder Neoplasms (52) · Melanoma (45) · Kidney Neoplasms (35) · Carcinoma, Transitional Cell (29) · Ovarian Neoplasms (27) · Colorectal Neoplasms (26) · Neoplasm Metastasis (25) · Squamous Cell Carcinoma of Head and Neck (25) · Stomach Neoplasms (23) · Triple Negative Breast Neoplasms (23) · Neoplasms (21) · Sarcoma (21) · Breast Neoplasms (18)
Female Urogenital Diseases (171) · Female Urogenital Diseases and Pregnancy Complications (171) · Male Urogenital Diseases (171) · Neoplasms by Site (171) · Urogenital Diseases (171) · Urogenital Neoplasms (169) · Urologic Diseases (167) · Neoplasms (150) · Neoplasms by Histologic Type (150) · Neoplasms, Glandular and Epithelial (144) · Carcinoma (134) · Kidney Diseases (124) · Adenocarcinoma (113) · Kidney Neoplasms (94)
pembrolizumab (23) · Cyclophosphamide (15) · Nivolumab (15) · fludarabine (10) · Cisplatin (7) · Gemcitabine (7) · Sunitinib (7) · aldesleukin (6) · atezolizumab (6) · Bevacizumab (5) · Carboplatin (5) · Interleukin-2 (5) · Radiosurgery (5) · avelumab (5) · spartalizumab (5)
National Cancer Institute (NCI) (15) · Pfizer (10) · M.D. Anderson Cancer Center (5) · Novartis Pharmaceuticals (5) · Celldex Therapeutics (3) · Genmab (3) · Hoffmann-La Roche (3) · Masonic Cancer Center, University of Minnesota (3) · Seagen Inc. (3) · ADC Therapeutics S.A. (2) · AbbVie (2) · Astellas Pharma Global Development, Inc. (2) · Brown University (2) · Calithera Biosciences, Inc (2) · Eli Lilly and Company (2)
United States (153) · Spain (20) · United Kingdom (16) · Canada (15) · Australia (13) · France (13) · Italy (12) · Japan (9) · Belgium (8) · South Korea (7) · Taiwan (7) · Denmark (6) · Germany (5) · China (4) · Czechia (4)
Steven A Rosenberg, M.D. (4) · Sam Whiting, MD, PhD (2) · Admasu Mamuye, MD (1) · AeRang Kim, MD, PhD (1) · Akhil Kumar, MD (1)
PMID 20305636, PMID 23377668, PMID 23861247, PMID 24456794, PMID 24914044, PMID 25052451, PMID 27286790, PMID 29322091, PMID 29735994, PMID 30190302, PMID 31401903, PMID 31654285, PMID 32238921, PMID 32472319, PMID 32524319, PMID 33305087, PMID 33507454, PMID 33883177, PMID 33909232, PMID 34187739, PMID 34562230, PMID 34686340, PMID 34965890, PMID 35444059, PMID 36041086, PMID 36536472, PMID 36803840, PMID 37093350, PMID 37129197, PMID 37311055, PMID 37369081, PMID 37637935, PMID 37651261, PMID 37798538, PMID 38215355, PMID 38372949, PMID 39209782, PMID 39214047, PMID 39462179, PMID 39816915, PMID 39945382, PMID 40549043, PMID 40580957, PMID 40592738, PMID 41389341, PMID 41724817, PMID 41912269, PMID 42259602, PMID 42580817
2017 (4), 2018 (4), 2019 (4), 2023 (3), 2015 (2), 2016 (2), 2009 (1), 2014 (1), N01CM62204 (1), P30CA008748 (1), P30CA013330 (1), P30CA014089 (1), P30CA015083 (1), P30CA016059 (1), P30CA016672 (1)